Primary diffuse large B-cell lymphoma of the major salivary glands: Increasing incidence and survival

被引:5
作者
Gupta, Avigeet [1 ,2 ]
Lee, Joshua A. [1 ,3 ]
Nguyen, Shaun A. [1 ]
Lentsch, Eric J. [1 ]
机构
[1] Med Univ South Carolina, Dept Otolaryngol Head & Neck Surg, Charleston, SC 29425 USA
[2] Univ Oklahoma, Dept Otolaryngol Head & Neck Surg, Hlth Sci Ctr, Andrews Acad Tower,Suite 1400, Oklahoma City, OK 73104 USA
[3] Univ Illinois, Dept Otolaryngol Head & Neck Surg, Chicago, IL USA
关键词
Diffuse large B-cell lymphoma; Salivary gland; SEER; Incidence; Survival; PAROTID-GLAND; PROGNOSIS;
D O I
10.1016/j.amjoto.2021.102938
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Background: Diffuse Large B-Cell Lymphoma (DLBCL) of the major salivary glands is a rare high-grade malignancy that often presents with vague symptoms. This study aimed to evaluate its incidence and prognosis on a population level. Methods: The Surveillance, Epidemiology, and End Results database was queried for cases of major salivary gland DLBCL. Results: 896 patients had DLBCL affecting the parotid gland (78.3%) or submandibular gland (19.8%). The incidence was increasing at 1.5% (P = 0.005) per year from 1973 to 2016. 24.4% of patients underwent parotidectomy, 16% had biopsy, and the remaining provided no details of diagnostic method. Five-year diseasespecific survival increased from 59.8% to 84.0%. Late-stage disease (HR = 1.7, P = 0.003) and female sex (HR = 2.1, P = 0.018) were associated with increased risk of mortality. Conclusion: Despite the rising incidence of major salivary gland DLBCL, chemotherapy and radiation treatment has resulted in increasingly favorable survival outcomes. The otolaryngologist - head and neck surgeon continues to play a critical role in establishing the diagnosis of salivary gland DLBCL.
引用
收藏
页数:5
相关论文
共 23 条
[1]  
BURTON GV, 1990, ARCH OTOLARYNGOL, V116, P69
[2]   CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. [J].
Coiffier, B ;
Lepage, E ;
Brière, J ;
Herbrecht, R ;
Tilly, H ;
Bouabdallah, R ;
Morel, P ;
Van den Neste, E ;
Salles, G ;
Gaulard, P ;
Reyes, F ;
Gisselbrecht, C .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) :235-242
[3]  
Coran, 2012, HODGKIN LYMPHOMA NON, P517, DOI DOI 10.1016/B978-0-323-07255-7.00038-6
[4]   Parotid lymphoma in west Scotland: two-year 'snapshot' of diagnosis, management and core issues [J].
Crampsey, D. P. ;
Savage, S. A. ;
McKay, P. ;
MacKenzie, K. .
JOURNAL OF LARYNGOLOGY AND OTOLOGY, 2009, 123 (11) :1237-1241
[5]   Parotid Gland Lymphoma: Prognostic Analysis of 2140 Patients [J].
Feinstein, Aaron J. ;
Ciarleglio, Maria M. ;
Cong, Xiangyu ;
Otremba, Michael D. ;
Judson, Benjamin L. .
LARYNGOSCOPE, 2013, 123 (05) :1199-1203
[6]  
FREEMAN C, 1972, CANCER, V29, P252, DOI 10.1002/1097-0142(197201)29:1<252::AID-CNCR2820290138>3.0.CO
[7]  
2-#
[8]  
GLEESON MJ, 1986, CANCER-AM CANCER SOC, V58, P699, DOI 10.1002/1097-0142(19860801)58:3<699::AID-CNCR2820580317>3.0.CO
[9]  
2-E
[10]   Underascertainment of radiotherapy receipt in Surveillance, Epidemiology, and End Results registry data [J].
Jagsi, Reshma ;
Abrahamse, Paul ;
Hawley, Sarah T. ;
Graff, John J. ;
Hamilton, Ann S. ;
Katz, Steven J. .
CANCER, 2012, 118 (02) :333-341